Abcam, ab249016, Anti-EAF2 antibody [EPR7117(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal EAF2 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR7117(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249016 is the carrier-free version of
ab151692
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EAF2 also known as ELL-associated factor 2 plays an important role in transcription regulation. This protein weighing approximately 32 kDa interacts with the ELL (eleven-nineteen lysine-rich leukemia) family of RNA polymerase II elongation factors. EAF2 expression is noted in various tissues including the prostate colon and liver indicating a broad impact on cellular functions across the body. Researchers often study EAF2 for its regulatory abilities and its influence on gene expression.
Biological function summary
EAF2 regulates the transcription elongation process. It works as part of a complex with ELL proteins impacting the rate at which RNA polymerase II can transcribe genetic information into messenger RNA. The EAF2-ELL complex stabilizes and enhances the transcription process ensuring proper gene expression and cellular function. Its influence on transcription shapes how cells respond to their environment making EAF2 a protein of interest in many studies.
Pathways
EAF2 significantly impacts the androgen receptor signaling pathway and transcriptional regulation pathways. In the androgen receptor pathway EAF2 influences gene expression by modulating the activity of this receptor affecting processes such as cell growth and differentiation. Furthermore it interacts with other proteins within these pathways including androgen receptor itself and transcriptional machinery components like RNA polymerase II linking it to cellular proliferation and hormone response.
EAF2 has a connection to prostate cancer and chronic liver disease. Its role in prostate cancer stems from its involvement in androgen receptor pathways where aberrant expression or dysfunction might contribute to tumor development and progression. EAF2 interacts with other proteins like ELL and androgen receptors making it a potential target for cancer therapy. In chronic liver disease understanding EAF2's contributions to transcription regulation might reveal its role in liver physiology and pathology providing insights into disease mechanisms and potential treatment strategies.